Your session is about to expire
← Back to Search
Tiragolumab + Atezolizumab for Non-Small Cell Lung Cancer
Study Summary
This trial will test a new two-drug combo as a possible treatment for lung cancer. The drugs will be given before surgery, and then again after surgery if it is successful.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can be treated with platinum-based chemotherapy.My cancer can be measured by scans.My lung cancer is either small cell or has small cell components.I have not had any cancer other than NSCLC in the last 5 years, except for those unlikely to spread or be fatal.My lung cancer is confirmed to be at a specific stage and type.I am fully active or restricted in physically strenuous activity but can do light work.My lungs work well enough for surgery to remove my cancer.I have active tuberculosis.My cancer has a ROS1 gene change.We need a sample of your tumor to check for a specific protein called PD-L1.You tested negative for HIV before screening.I am currently receiving treatment that boosts my immune system.My health, aside from lung cancer, does not limit my life expectancy.My lung cancer is a specific type, like large cell neuroendocrine or sarcomatoid.I have previously been treated with specific immune therapies.You have or had a condition where your immune system attacks your own body, or your immune system is weak.I haven't had a severe infection in the last 4 weeks.I am currently taking medication that weakens my immune system.I have a history of specific lung conditions or signs of lung inflammation on a CT scan.You don't have active hepatitis B or C.My lung cancer has a specific genetic change.I have a serious heart condition.My blood and organs are functioning well.My cancer can be completely removed with surgery aimed at curing it.I have received treatment for lung cancer before.
- Group 1: Cohort A (PD-L1 High)
- Group 2: Cohort B (PD-L1 All Comers)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you list any other trials that have leveraged Atezolizumab?
"Atezolizumab was first researched in 1997 at the City of Hope Comprehensive Cancer Center, and so far 2937 studies have been conducted. Currently 1956 trials are actively recruiting patients, with a large proportion based out of Westwood Kansas."
Has Atezolizumab received regulatory approval from the FDA?
"Our evaluation of the safety profile of Atezolizumab is a 2, considering that this is a Phase-2 trial with limited evidence supporting efficacy but some data suggesting its safe use."
Is there currently an open enrollment period for this research project?
"Affirmative. According to information posted on clinicaltrials.gov, this medical trial is currently accepting participants; the study was first made available on April 23rd 2021 and updated most recently in November 22nd 2022. Eighty-two individuals are required across 11 trial sites."
What therapeutic treatments does Atezolizumab typically target?
"Atezolizumab is a popular therapeutic option for metastatic ureter urothelial carcinoma and has been proven useful in treating lymphomas, non-hodgkin, locally advanced non-small cell lung cancer during its first administration."
How many participants are taking part in this research initiative?
"In order to administer this project, 82 participants who meet the inclusivity requirements are necessary. The sponsor of the trial, Hoffmann-La Roche, will be managing data collection from University of Kansas Cancer Center (Westwood) and Winthrop Univ Hospital (Mineola)."
How many separate venues are overseeing this research endeavor?
"At present, 11 clinical trial sites are operating in tandem. These locations span Westwood, Mineola and Los Angeles as well other nearby cities. We suggest selecting the nearest site to minimize travelling requirements for prospective participants."
Share this study with friends
Copy Link
Messenger